Interferon is an immune stimulating agent. According to an article recently published in the Annals of Surgery, administration of interferon following surgery may improve survival among patients with advanced hepatitis B-related hepatocelluar carcinoma.

Hepatocelluar carcinoma (HCC) is the most common type of liver cancer. Unfortunately for this disease, recurrences often happen after surgical removal of the cancer. Researchers continue to evaluate ways to reduce these recurrences.

A clinical trial was conducted to evaluate the use of interferon following surgery in patients with HCC. The trial included 80 patients, one group received the interferon after surgery and the other group received no further treatment. The researchers found that the group treated with interferon experienced better survival rates.

The Food and Drug Administration (FDA) will take an additional three months to review Wyeth's kidney cancer drug Torisel -- the first of five new medications the company plans to introduce this year.

The FDA needs more time to investigate data on tumor growth in patients taking Torisel. If all goes well, the drug will be one of only three to effectively hold off incurable kidney cancer. The other two drugs are Pfizer's Sutent and Bayer AG's Nexavar.

Robert Ruffolo, president of Wyeth Research, says he is encouraged by the review process so far. And he is optimistic about launching the product in late 2007.

Studies show Torisel, which will cost patients about $30,000 per year, prolonged survival by 50 percent in those faring poorly with kidney cancer. The sickest kidney-cancer patients were essentially kept alive for 10.9 months, compared with 7.3 months with interferon drugs. Torisel also postponed tumor growth for 5.5 months. This is 77 percent longer than with interferon.

Sutent and Nexavar, both on the market since last year, also slow tumor growth. All three kidney-cancer medicines are of the variety that block the growth of cancer cells -- different from standard chemotherapy which kills tumors and harms nearby tissues too.

Wyeth is relatively new to the oncology market. And soon, the company hopes to launch three more cancer drugs. One, called CMC-544, treats non-Hodgkin's lymphoma. Another, SKI-606, is for chronic myelogenous leukemia. And the third, HKI-272, is for breast cancer.

About 51,000 Americans will be diagnosed with kidney cancer this year.

At one time, patients with blood cancers were treated with harsh drugs, like interferon or hydroxyurea, yet only two to three percent would ever achieve any sort of remission. Many would suffer such extreme side effects from these drugs they would stop taking the medication early, decreasing even further their potential odds for survival.

The fate of these patients is changing. And the proof is in print -- in today's issue of the New England Journal of Medicine.

It all began with the study of a highly targeted molecular therapy called STI571 -- designed to block the genetic aberration that gives rise to chronic myeloid leukemia (CML), a disease that affects about 6,000 Americans every year. A clinical trial followed, and a compound marketed by the drug company Novartis emerged. Today, this compound is know as Gleevec.

In the clinical trial of Gleevec, 1,106 CML patients were randomly chosen to receive either Gleevec or Interferon. Early results were so encouraging that all but three percent of the participants using Interferon switched to Gleevec. Five-year survival rates were 89 percent. And 93 percent of patients saw no progression to the acute phase of the disease. Many patients witnessed their blood counts return to normal, and a large number experienced a reverse in the gene mutation that causes CML. Virtually no one reported side effects while using the drug.

Despite a rare reaction that can cause heart failure, Gleevec has now been approved by the FDA for the treatment of six other rare, life-threatening disorders. And other drugs similar in nature to Gleevec are hitting the scene. Some believe long-term suppression of CML will come from a cocktail of these types of drugs.

For now, Gleevec -- on its own -- is a success story.

Late last March fans of rock legend and Aerosmith lead singer Steven Tyler became concerned over speculation that Tyler had been diagnosed with throat cancer. Even though the remaining Rockin' The Joint show dates were cancelled, everyone connected to Tyler assured the public the rumors were false. Steven Tyler did not have cancer. He was suffering from strained vocal cords and needed a rest.

At the time, bassist Tom Hamilton explained the cancelled shows by saying, "You know Steven. Anything worth doing, to him, is worth overdoing," in reference to the fact that the band had been touring more now than it did 10 years ago.

Unfortunately, several months later it was announced that Hamilton had been diagnosed with cancer.

While the rumors had quieted concerning Tyler's health, now and then something new would come to our attention that made us wonder if he was okay. A reader wrote in that he had seen Tyler at the oncology clinic at a hospital he was visiting. We kept that under our hat.

Last night, Tyler appeared on Access Hollywood and for the first time, publicly discussed his health. No, he was not diagnosed with throat cancer -- but he had faced a serious health crisis and decided to speak about it. Tyler said he had been fighting a secret battle with a silent killer -- Hep C. Diagnosed three years ago, he was told by his doctor, Deepak Chopra's brother, that it was time he sought treatment. Tyler agreed to undergo a year of chemotherapy with interferon. He stated it nearly killed him but managed to stay with it and complete treatment. Tyler had Hep C for many years, and was asymptomatic, which is typical.

During the interview, Tyler said, "Hepatitis C is the one that, of all the people in this room, at least three have it and don't know it." He would like to raise awareness about Hep C and mentioned he might appear on Oprah for that purpose. "It's one of those things people don't speak about it, but it is treatable."

Almost 4 million Americans, or 1.8 percent of the U.S. population, have been infected with hepatitis C virus (HCV); it is the most prevalent cause of chronic liver disease in the United States. 80 percent of those with Hep C have no symptoms. Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer.

If you missed the television Access Hollywood interview with Steven Tyler, the video segment of the program is available online here.

Did you know almost 4 million Americans, or 1.8 percent of the U.S. population, have been infected with hepatitis C virus (HCV); it is the most prevalent cause of chronic liver disease in the United States; and a segment of those suffering from chronic HCV, or Hep C, will develop liver cancer. Until this morning, I did not know.

But when someone close to you is diagnosed with this disease, numbers do not matter. Even if there were only two people on the planet with this diagnosis and one of the two happens to be someone you love, then it suddenly seems to become the number one disease.

In my preliminary research, I have found that 80 percent of those with Hep C have no symptoms. If symptoms do occur, they are likely to be jaundice; fatigue; dark urine; abdominal pain; loss of appetite and nausea. Skin rashes, extreme itching, muscle wasting and weight loss can also be signs of Hep C. For decades, you can have Hep C and not know it is taking its toll on the liver.

According to the National Digestive Diseases Information Clearinghouse (NDDIC), a distinct and major characteristic of hepatitis C is its tendency to cause chronic liver disease. At least 75 percent of patients with acute hepatitis C ultimately develop chronic infection, and most of these patients have accompanying chronic liver disease. Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer.

Those at highest risk for Hep C are intravenous drug users; recipients of clotting factors made before 1987; hemodialysis patients; recipients of blood and/or solid organs before 1992; healthcare workers, and infants born to infected mothers.

The treatments are harsh and can come with severe side effects that cause some to discontinue treatment. New research indicates that smoking marijuana seems to offset some of the adverse side effects of treatment and help those fighting this disease remain on treatment. Hepatitis Central has published an explanation of how Hep C infection can lead to liver cancer with Duke Researchers Show How Hepatitis Infection Leads To Liver Cancer, that I found helpful in understanding the progression of the disease.

As I say, I have just started my research this morning. With a critical eye, I will continue researching until I have exhausted every avenue of information, both conventional and alternative, that I can find. If any of our readers can suggest any resources for Hep C and/ or liver cancer, please leave this information in the comment area.

Interferon is an agent that stimulates the immune cells to help fight cancer. In an article published in Bone Marrow Transplantation it said that the addition of interferon following an autologous stem cell transplant improves survival for children with recurrent Hodgkin's lymphoma.

Patients that have their Hodgkin's lymphoma return after initial treatment may undergo an autologous stem cell transplant. In an autologous stem cell transplant a patients own cells are collected prior to high-dose chemotherapy and then re-infused.

The researchers wanted to evaluate whether the addition of interferon to the stem cell transplant could improve outcomes. The trial included 13 children with recurrent Hodgkin's lymphoma who were treated with an autologous stem cell transplant. Ten of these patients then went on to receive the interferon.

Follow up at five years shows that nine of the ten patients treated with interferon are alive and cancer free. The researchers concluded that interferon provided significant anticancer activity following the transplant.

Cancer, regardless of the type, is the result of two occurrences:

• Mutations of our genetic material (DNA and RNA).
• Failure of our immune system to detect and destroy the resulting genetic mutation.
  

Everyone has thousands of pre-cancerous cells occurring all the time. In most people, their immune systems are healthy enough to detect and destroy these before they grow into cancer. The cancer patient's immune system is not doing this job properly. The latest research tells us that when levels of one or more of the eight necessary glyconutrients (mannose, fucose, xylose, glucose, galactose, n-acetyl-neuramic acid, n-acetyl-glucosamine, and n-acetyl-glalactosamine) become low, cancer can result.

For example, abnormal mannose and N-acetylglucosamine sugars have been found in breast and colon cancer cells.  In addition, a lack of these glyconutrients have been linked to the spread of cancer cells throughout the body.  What we now know is that we are all deficient in dietary glyconutrients today, thus opening us up to cancer, and other diseases.

• Glyconutrients stimulate macrophage and immune killer cells to destroy cancer (this is the first line of defense).
• They increase the production of substances like interferon to target and destroy malignant cells.
• They activate T-cells to recognize invaders and destroy them (second line of defense).
• They help to regulate when cells die off (apoptosis). When this safety mechanism fails, cancer cells are allowed to keep replicating.
  

There are some top oncologists who are using glyconutrients in their daily practice -- insisting that their patients get on these life-changing supplements.  The discovery of glyconutrients and how cells communicate just occurred a few years ago, long after your doctor left medical school.  Unfortunately, glyconutrients are not in the educational program by pharmaceutical companies presented to your doctor because they are natural supplements, not drugs.  The American Medical Association, AMA, has sanctioned continuing medical education seminars so doctors can begin learning this vital new information. The AMA have never sanctioned seminars for any natural supplement technology before -- that's how important the medical community believes glyconutrients to be.